Zhiyu He

Lanzhou University, Kao-lan-hsien, Gansu Sheng, China

Are you Zhiyu He?

Claim your profile

Publications (5)13.57 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare the efficacy between left radial approach (LRA) and right radial approach (RRA) for coronary angiography (CAG). The following databases were searched, including PubMed, Embase, Web of science, Cochrane Library, CBM, VIP, Wanfang databases and CNKI, from creation of database to January 2013. Two reviewers extracted data independently, according to inclusive criteria, exclusion criteria and methods of Cochrane Collaboration. Statistical analysis was performed using Review Manager Software (RevMan 5.1). Eleven trials with 5 442 patients were included in the systematic review. The results of meta-analysis showed that when compared with RRA, LRA did not increase the failure rate of the procedures (OR = 1.04, 95%CI 0.80-1.35, P > 0.05) and amount of contrast medium (mean difference = 2.39, 95%CI -0.30-5.08), P > 0.05). However, LRA was superior to RRA in reducing fluoroscopy time (standardized mean difference = 0.15, 95%CI 0.06-0.24, P < 0.01). In addition, the incidence of severe tortuosity of subclavian artery was significantly lower with LRA (OR = 4.65, 95%CI 1.98-10.88, P < 0.01). Based on the current evidence, LRA shares similar safety with RRA for CAG and is superior to RRA in certain respects. LRA can thus be used either as an alternative approach or routine approach for CAG.
    Zhonghua xin xue guan bing za zhi [Chinese journal of cardiovascular diseases] 03/2014; 42(3):241-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epidemiological evidences indicate that individuals with diabetes may have an increased risk of acute pancreatitis. Therefore, we carried out a meta-analysis to examine the present evidence and to identify the association between type 2 diabetes mellitus and the risk of acute pancreatitis. All observational studies and randomized-controlled trials evaluating the relationship between type 2 diabetes mellitus and the risk of acute pancreatitis were identified in PubMed (January 1966), Embase (January 1974), Web of Science (January 1986), and Cochrane Library, through March 2012. Relative risk with the corresponding 95% confidence interval was pooled using STATA 12.0. A total of seven observational studies with 15 298 024 patients were identified for the meta-analysis. Meta-analysis of these observational studies showed that type 2 diabetes mellitus was associated with an increased risk of acute pancreatitis (relative risk=1.84; 95% confidence interval 1.45-2.33; P=0.000), with significant heterogeneity (P=0.000, I=93.7%). The positive association was consistent in subgroup analyses according to the study design, geographic area, and sex. Our sensitivity analyses also confirmed the stability of the association. No significant publication bias was observed. These outcomes strongly support the relationship between type 2 diabetes mellitus and an increased risk of acute pancreatitis. More fundamental research should be carried out to elucidate the biological mechanisms.
    European journal of gastroenterology & hepatology 02/2013; 25(2):225-31. DOI:10.1097/MEG.0b013e32835af154 · 2.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence. All observational studies and randomized controlled trials evaluating the relationship of insulin glargine and cancer risk were identified in PubMed, Embase, Web of Science, Cochrane Library and the Chinese Biomedical Medical Literature Database, through March 2012. Odds ratios (ORs) with corresponding 95% confidence interval (CI) were calculated with a random-effects model. Confidence in the estimates of the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach. A total of 11 studies including 448,928 study subjects and 19,128 cancer patients were finally identified for the meta-analysis. Insulin glargine use was associated with a lower odds of cancer compared with non-glargine insulin use (OR 0.81, 95% CI 0.68 to 0.98, Pā€Š=ā€Š0.03; very low-quality evidence). Glargine did not increase the odds of breast cancer (OR 0.99, 95% CI 0.68 to 1.46, Pā€Š=ā€Š0.966; very low-quality evidence). Compared with non-glargine insulin, no significant association was found between insulin glargine and prostate cancer, pancreatic cancer and respiratory tract cancer. Insulin glargine use was associated with lower odds of other site-specific cancer. Results from the meta-analysis don't support the link between insulin glargine and an increased risk of cancer and the confidence in the estimates of the effects is very low. Further studies are needed to examine the relation between insulin glargine and cancer risk, especially breast cancer.
    PLoS ONE 12/2012; 7(12):e51814. DOI:10.1371/journal.pone.0051814 · 3.53 Impact Factor
  • Zhiyu He, Lin Yang, Yali Yao
    The Canadian journal of cardiology 10/2012; DOI:10.1016/j.cjca.2012.08.006 · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The effects of omega-3 fatty acids (PUFA) on the prevention of atrial fibrillation (AF) appear to contrast between several randomized controlled trials (RCTs). Therefore, we performed a meta-analysis to assess the efficacy and safety of PUFA for the primary and secondary prevention of AF. METHODS: PubMed, EMBASE, Web of Science, Cochrane Library and the Chinese Biomedical Literature Database were searched for randomized controlled trials (published up to January 2012) that compared PUFA with control. All statistical analyses were performed with RevMan (version 5.1; The Cochrane Collaboration, Oxford, United Kingdom). RESULTS: For primary prevention after open heart surgery: 6 studies with 928 patients were designed to evaluate the effects of PUFA on the incidence of postoperative AF. The use of PUFA significantly reduced the incidence of postoperative AF (odds ratio [OR] 0.66; 95% confidence interval [CI], 0.49 to 0.88; P = 0.004); there was no difference in complications or adverse events (OR, 1.24; 95% CI, 0.58-2.62; P = 0.58). For secondary prevention, we analyzed 5 studies involving 1256 patients designed to evaluate the effects of PUFA therapy on AF. The use of PUFA did not significantly reduce the recurrence of AF (OR, 0.74; 95% CI, 0.39-1.42; P = 0.37); no difference was observed in complications or adverse events (OR, 1.10; 95% CI, 0.78-1.57; P = 0.58). CONCLUSIONS: The meta-analysis shows that PUFA therapy is significantly associated with a decreased odds of incidence of AF after open heart surgery, but there is no significant difference in recurrence of AF between PUFA and control groups. PUFA is well-tolerated, with no difference in complications or adverse events between PUFA and control groups.
    The Canadian journal of cardiology 06/2012; 29(2). DOI:10.1016/j.cjca.2012.03.019 · 3.94 Impact Factor